Infectious Plasmodium sporozoites grown in vitro

Inventors

EAPPEN, Abraham G. • Hoffman, Stephen L

Assignees

Sanaria Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11883475-B2

Patent

Publication Date

2024-01-30

Expiration Date


Abstract

The application is directed to in vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.

Core Innovation

The invention provides in vitro-reared mature infectious Plasmodium sporozoites of human host range in which sporogony from gametocyte stage to mature sporozoite stage occurs external to mosquitoes and is absent any mosquito material. The in vitro-reared mature infectious Plasmodium sporozoites retain the ability to infect a host and invade hepatocytes within the liver, while arresting development in liver-stage.

In the in vitro-reared mature infectious Plasmodium sporozoites of human host range, the genome comprises a gene alteration or mutation. The gene alteration or mutation disrupts the function of one or more genes, producing sporozoites that preserve infectivity and hepatocyte invasion capacity despite disruption of development at liver-stage.

The disclosed work also defines a method of culturing genetically attenuated Plasmodium parasites of human host range in vitro during sporogonic development, progressing from gametocyte stage to zygote stage, then differentiating to ookinetes, then differentiating to mature sporozoites, and harvesting the genetically attenuated parasites at a mature sporozoite stage. A culture is further described comprising in vitro-reared parasites at the zygote stage that have undergone sporogonic development in vitro together with a culture medium, including an exflagellation medium.

The described system further supports vaccine-related use, including vaccine compositions that comprise in vitro-reared mature infectious Plasmodium sporozoites of human host range and pharmaceutically acceptable excipients, diluents, or carriers, and methods for inducing an immune response in a subject against Plasmodium-specific antigens by administering the vaccine composition.

Claims Coverage

The provided independent claims define three inventive features centered on mosquito-absent sporogony, genetic attenuation via gene disruption, and staged in vitro sporogonic development, with additional coverage for vaccine composition and immune-response induction in dependent claims.

Mosquito-absent external sporogony with infectious hepatocyte invasion but liver-stage arrest

In vitro-reared mature infectious Plasmodium sporozoites of human host range, wherein sporogony from gametocyte stage to mature sporozoite stage is external to mosquitoes and absent any mosquito material, and wherein the genome comprises a gene alteration or mutation that disrupts the function of one or more genes, such that the sporozoites retain the ability to infect a host and invade hepatocytes within the liver, but arrest development in liver-stage.

Staged in vitro sporogonic development from gametocyte to mature sporozoite

A method of culturing genetically attenuated Plasmodium parasites of human host range in vitro during sporogonic development, comprising progression from gametocyte stage to zygote stage, differentiation to ookinetes, differentiation to mature sporozoites, and harvesting the genetically attenuated parasites at a mature sporozoite stage.

Zygote-stage in vitro sporogonic culture with culture medium

A culture comprising in vitro-reared Plasmodium parasites of human host range and a culture medium, wherein the parasites are at the zygote stage of development and have undergone sporogonic development in vitro.

Overall, the claims cover mosquito-absent external sporogony producing genetically altered infectious sporozoites that invade hepatocytes but arrest development in liver-stage, a corresponding staged in vitro culturing method for genetically attenuated parasites through sporogonic development, and an in vitro culture defined at the zygote stage with a culture medium.

Stated Advantages

Retain the ability to infect a host and invade hepatocytes within the liver while arresting development in liver-stage.

Documented Applications

Vaccine compositions that include in vitro-reared mature infectious Plasmodium sporozoites of human host range with pharmaceutically acceptable excipients, diluents, or carriers.

Inducing an immune response in a subject against Plasmodium-specific antigens by administering the vaccine composition.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.